by Elisabeth Reitman, Yale University Credit: Pixabay/CC0 Public Domain Research led by Muhammad Riaz, Ph.D., Jinkyu Park, Ph.D., and Lorenzo Sewanan, MD, Ph.D., from the Qyang and Campbell laboratories at Yale, provides a mechanism to identify abnormalities linked with a hereditary cardiac condition, hypertrophic cardiomyopathy (HCM), in which walls of the left ventricle become abnormally...
Megan Brooks April 29, 2022 The US Food and Drug Administration (FDA) has approved mavacamten (Camzyos, Bristol Myers Squibb) to improve functional capacity and symptoms in adults with symptomatic New York Heart Association (NYHA) class II to III obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten is the first FDA-approved allosteric and reversible inhibitor selective for cardiac myosin...
CEDARS-SINAI MEDICAL CENTER A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session in Washington, D.C. Florian Rader, MD, MSc, associate professor of Cardiology and medical director of the Hypertension Center in the Smidt Heart...
CLEVELAND CLINIC EMBARGOED UNTIL 9:30A.M. ET., Saturday, April 2nd, 2022, Cleveland: Findings from a Cleveland Clinic-led clinical trial showed that the use of an experimental drug in severely symptomatic, hypertrophic cardiomyopathy patients significantly reduced the need for invasive procedures. The trial evaluated whether the drug, mavacamten, could be used as an alternative to heart surgery...
by Melinda Krigel, University of California, San Francisco Credit: Pixabay/CC0 Public Domain Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden death in adolescents and initial detection is often difficult. A new UC San Francisco study finds that Artificial Intelligence-enhanced (AI)-Electrocardiograms (ECG) may help identify the condition in its earliest stages and monitor important disease-related...
CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.) IMAGE: SCHEME OF A CMYBP-C REGION IN WHICH MUTATIONS CAUSE AMINO-ACID CHANGES THAT ALTER THE MECHANICAL PROPERTIES OF THE PROTEIN. THE POSITIONS OF THE AFFECTED AMINO ACIDS ARE SHOWN IN RED. CREDIT: CNIC Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have described a potential disease-causing...
AMERICAN HEART ASSOCIATION DALLAS, Nov. 9, 2020 — The new, investigational heart medication mavacamten may improve key structural abnormalities of obstructive hypertrophic cardiomyopathy, a condition characterized by thickened heart muscle that obstructs pumping of blood through the heart, according to research from the Phase 3 EXPLORER-HCM trial, to be presented at the American Heart Association’s Scientific Sessions...
